medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2010, Número 1

<< Anterior Siguiente >>

Rev Invest Clin 2010; 62 (1)


Resistencia de las vías aéreas y LTE4 urinario en niños con displasia broncopulmonar. Informe preliminar

Vargas MH, Ojeda-Luna NG, Furuya MEY, Arreola-Ramírez JL, Zúñiga-Vázquez G

Idioma: Español
Referencias bibliográficas: 43
Paginas: 15-22
Archivo PDF: 91.35 Kb.


RESUMEN

Objetivo. Conocer la resistencia de las vías aéreas y la concentración urinaria de leucotrieno E4 (LTE4) antes y después de la inhalación de salbutamol en niños con displasia broncopulmonar (DBP). Material y métodos. En un estudio transversal en niños con DBP se midió la resistencia de las vías aéreas por el método de la interrupción (Rint) y se cuantificaron los niveles de LTE4 urinario por inmunoanálisis antes y después de inhalar 200 µg de salbutamol. Resultados. Estudiamos 31 niños con DBP (15 mujeres) con edades entre tres meses y nueve años. Nuestros resultados mostraron que el LTE4 no correlacionó con los valores de Rint (r = 0.12, p = 0.52) incluso después de ajustar por género, antecedente de atopia, uso de esteroide y reflujo gastroesofágico. De igual forma, el LTE4 no correlacionó con el grado de respuesta bronquial al salbutamol (r = -0.13, p = 0.50). Se encontró una fuerte asociación inversa entre la edad y la Rint (r = -0.58, p ‹ 0.001). Conclusión. En niños con DBP el LTE4 urinario no correlacionó con la resistencia de las vías aéreas o con la respuesta a un agente broncodilatador, sugiriendo que los leucotrienos no participan en la obstrucción de la vía aérea en esta enfermedad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respiratory therapy of hyaline membrane disease: bronchopulmonary dysplasia. N Engl J Med 1967; 276: 357-68.

  2. Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med 2007; 357: 1946-55.

  3. Kraemer R. Whole body plethysmography in the clinical assessment of infants with bronchopulmonary diseases. Respiration 1993; 60: 1-8.

  4. Gross SJ, Anbar RD, Mettelman BB. Follow-up at 15 years of preterm infants from a controlled trial of moderately early dexamethasone for the prevention of chronic lung disease. Pediatrics 2005; 115: 681-7.

  5. Smyth JA, Tabachnik E, Duncan WJ, Reilly BJ, Levison H. Pulmonary function and bronchial hyperreactivity in long term survivors of bronchopulmonary dysplasia. Pediatrics 1981; 68: 336-40.

  6. Bader D, Ramos A, Lew CD, Platzker ACG, Stabile MW, Keens TG. Childhood sequelae of infant lung disease: exercise and pulmonary function abnormalities after bronchopulmonary dysplasia. J Pediatr 1987; 110: 693-9.

  7. Greenough A. Late respiratory outcomes after preterm birth. Early Hum Dev 2007; 83: 785-8.

  8. Wood-Baker R, Town GI, Benning B, Holgate ST. The reproducibility and effect on non-specific airway responsiveness of inhaled prostaglandin D2 and leukotriene D4 in asthmatic subjects. Br J Clin Pharmacol 1995; 39: 119-23.

  9. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med 2007; 357: 1841-54.

  10. Kumlin M. Measurement of leukotrienes in humans. Am J Respir Crit Care Med 2000; 161: S102-S106.

  11. Groneck P, Gotze-Speer B, Opperman M, Effert H, Speer CP. Association of pulmonary inflammation and increased microvascular permeability during the development of BPD: a sequential analysis of inflammatory mediators in respiratory fluids of high risk preterm neonates. Pediatrics 1994; 93: 712-8.

  12. Mirro R, Armstead W, Leffler C. Increased airway leukotriene levels in infants with severe bronchopulmonary dysplasia. Am J Dis Child 1990; 144: 160-1.

  13. Motoyama E, Chaney H, Dworltz A. Early appearance of neutrophil chemotaxis leukotriene B4 (LTB4) and airway reactivity in infants with bronchopulmonary dysplasia. Am Rev Respir Dis 1986; 133(Suppl.): A207.

  14. Kohelet D. Variations in neutrophil count in preterm infants with respiratory distress syndrome who subsequently developed chronic lung disease. Am J Perinatol 2000; 17: 59-62.

  15. Cook AJ, Yuksel B, Sampson AP, Greenough A, Price JF. Cysteinyl leukotriene involvement in chronic lung disease in premature infants. Eur Respir J 1996; 9: 1907-12.

  16. Jobe AH, Bancalari E. NICHD/NHLBI/ORD Workshop Summary. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163: 1723-9.

  17. Fauler J, Frolich JC. Cigarette smoking stimulates cysteinyl leukotriene production in man. Eur J Clin Invest 1997; 27: 43-7.

  18. Davidson D, Drafta D, Wilkens B. Elevated urinary leukotriene E4 in chronic lung disease of extreme prematurity. Am J Respir Crit Care Med 1995; 151: 841-5.

  19. Sheikh S, Null D, Gentile D, Bimle C, Skoner D, McCoy K, et al. Urinary leukotriene E4 excretion during the fist month of life and subsequent bronchopulmonary dysplasia in premature infants. Chest 2001; 119: 1749-54.

  20. Dahlén SE. Treatment of asthma with antileukotrienes: first line or last resort therapy? Eur J Pharmacol 2006; 533: 40-56.

  21. Filippone M, Sartor M, Zacchello F, Baraldi E. Flow limitation in infants with bronchopulmonary dysplasia and respiratory function at school age. Lancet 2003; 361: 753-4.

  22. Korhonen P, Laitinen J, Hyödynmaa E, Tammela O. Respiratory outcome in school-aged, very-low-birth-weight children in the surfactant era. Acta Paediatr 2004; 93: 316-21.

  23. Doyle LW, Faber B, Callanan C, Freezer N, Ford GW, Davis NM. Bronchopulmonary dysplasia in very low birth weight subjects and lung function in late adolescence. Pediatrics 2006; 118: 108-13.

  24. Doyle LW, Ford GW, Olinsky A, Knoches AM, Callanan C. Bronchopulmonary dysplasia and very low birthweight: lung function at 11 years of age. J Paediatr Child Health 1996; 32: 339-43.

  25. Merkus PJFM, Mijnsbergen JY, Hop WCJ, de Jongste JC. Interrupter resistance in preschool children: measurement characteristics and reference values. Am J Respir Crit Care Med 2001; 163: 1350-5.

  26. McKenzie SA, Chan E, Dundas I, Bridge PD, Pao CS, Mylonopoulou M, Healy MJR. Airway resistance measured by the inte rrupter technique: normative data for 2-10 years old of three ethnicities. Arch Dis Child 2002; 87: 248-51.

  27. Beydon N, Amsallem F, Ballet M, Boule M, Chaussain M, Denjean A, et al. Pre/postbronchodilatador interrupter resistance values in healthy young children. Am J Respir Crit Care Med 2002; 156: 1388-94.

  28. Merkus PJ, Arets HG, Joosten T, Siero A, Brouha M, Mijnsbergen JY, et al. Measurements of interrupter resistance: reference values for children 3-13 yrs of age. Eur Respir J 2002; 20: 907-11.

  29. Lombardi E, Sly PD, Concutelli G, Novembre E, Veneruso G, Frongia G, et al. Reference values of interrupter respiratory resistance in healthy preschool white children. Thorax 2001; 56: 691-5.

  30. Arets M, Brackel L, Van Der Ent K. Applicability of interrupter resistance measurements using the MicroRint® in the daily practice. Respir Med 2003; 97: 366-74.

  31. Lanteri CJ, Sly PD. Changes in respiratory mechanics with age. J Appl Physiol 1993; 74: 369-78.

  32. Allen J, Zwerdling R, Ehrenkranz R, Gaultier C, Geggel R, Greenough A, et al. American Thoracic Society. Statement on the care of the child with chronic lung disease of infancy and childhood. Am J Respir Crit Care Med 2003; 168: 356-96.

  33. Baveja R, Christou H. Pharmacological strategies in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol 2006; 30: 209-18.

  34. Pelkonen A, Hakulinen AL, Turpeinen M. Bronchial lability and responsiveness in school children born very preterm. Am J Respir Crit Care Med 1997; 156: 1178-84.

  35. Wraight JM, Hancox RJ, Herbison GP, Cowan JO, Flannery EM, Taylor DR. Bronchodilator tolerance: the impact of increasing bronchoconstriction. Eur Respir J 2003; 21: 810-5.

  36. Kercsmar C. Asthma, Chernick V, Boat T. In: Disorders of the respiratory tract in children. (eds.). Philadelphia: Saunders; 1998, p. 688-730.

  37. Girodet PO, Berger P, Martínez B, Marthan R, Advenier C, Molimard M. Paradoxical effect of salbutamol in an in vitro model of bronchoprotection. Fundam Clin Pharmacol 2005;19:179-86.

  38. De Boeck K, Smith J, Van Lierde S, Devlieger H. Response to bronchodilators in clinically stable 1-year-old patients with bronchopulmonary dysplasia. Eur J Pediatr 1998; 157: 75-9.

  39. Robin B, Kim YJ, Huth J, Klocksieben J, Torres M, Tepper RS, et al. Pulmonary function in bronchopulmonary dysplasia. Pediatr Pulmonol 2004; 37: 236-42.

  40. Greenough A, Yuksel B, Cheeseman P. Effect of in utero growth retardation on lung function at follow-up of prematurely born infants. Eur Respir J 2004; 24: 731-3.

  41. Yuksel B, Greenough A. Variable response to bronchodilator therapy in young children born prematurely. Respir Med 1993; 87: 359-64.

  42. Yuksel B, Greenough A. Effect of nebulized salbutamol in preterm infants during the first year of life. Eur Respir J 1991; 4: 1088-92.

  43. Yuksel B, Greenough A. Relationship of symptoms to lung function abnormalities in preterm infants at follow-up. Pediatr Pulmonol 1991; 11: 202-6.




2020     |     www.medigraphic.com